{"id":"crizanlizumab-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL4297734","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P-selectin is an adhesion molecule that mediates the interaction between platelets, red blood cells, and endothelial cells, contributing to vaso-occlusive events in sickle cell disease. By blocking P-selectin, crizanlizumab reduces the adhesion of sickle cells to the endothelium and decreases platelet activation, thereby reducing the frequency and severity of vaso-occlusive crises. This mechanism addresses a key pathophysiological process in sickle cell disease without directly affecting hemoglobin polymerization.","oneSentence":"Crizanlizumab is a monoclonal antibody that binds to P-selectin on the surface of platelets and endothelial cells, blocking platelet-endothelial interactions and reducing vaso-occlusive crises in sickle cell disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:23.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sickle cell disease (reduction of vaso-occlusive crises in patients 16 years and older)"}]},"trialDetails":[{"nctId":"NCT05909618","phase":"PHASE2","title":"Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases","status":"RECRUITING","sponsor":"Sheba Medical Center","startDate":"2023-07-11","conditions":"Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated Glioblastoma","enrollment":33},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Crizanlizumab Injection","genericName":"Crizanlizumab Injection","companyName":"Matthew Neal MD","companyId":"matthew-neal-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Crizanlizumab is a monoclonal antibody that binds to P-selectin on the surface of platelets and endothelial cells, blocking platelet-endothelial interactions and reducing vaso-occlusive crises in sickle cell disease. Used for Sickle cell disease (reduction of vaso-occlusive crises in patients 16 years and older).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}